Versant Ventures
Markus Enzelberger is currently a Partner at Versant Ventures and an Entrepreneur in Residence involved in launching future newcos from Versant's Ridgeline Discovery Engine. Markus also holds board member positions at Matterhorn Biosciences, Granite Bio, Vector BioPharma, Ridgeline Discovery, and Cimeio Therapeutics. In addition, Markus serves as a Senior Advisor at SHS Capital and a Board Observer at T-knife. With a background in Applied Physics and Chemie, Markus Enzelberger has a wealth of experience in the bioscience industry.
This person is not in any offices
Versant Ventures
1 followers
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $2.4 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and clinical expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 70 Versant companies have achieved successful acquisitions or IPOs.